ArticleAmerican journal of translational research2022
Case series of unilateral biportal endoscopic-assisted transforaminal lumbar interbody fusion in the treatment of recurrent lumbar disc herniation.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.
- Efficacy and safety of unilateral biportal endoscopy for recurrent lumbar disc herniation: A quantitative analysis of 7 cohort studies involving 409 patients.Neurosurgical review · 2026Pooled it
- Comparing the efficacy and complications of unilateral biportal endoscopic fusion versus minimally invasive fusion for lumbar degenerative diseases: a systematic review and mate-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023Pooled it
- Advancements in unilateral biportal endoscopic lumbar interbody fusion: a narrative review.European journal of medical research · 2026Review
- Unilateral Biportal Endoscopic Spine Surgery: Managing Complex and Revision Cases With a Minimally Invasive Approach.Cureus · 2025Article
- Article
- Comparative Efficacy of Unilateral Biportal Endoscopy vs Traditional Surgery in Lumbar Degenerative Disorders.Medical science monitor : international medical journal of experimental and clinical research · 2024Observational
- Unilateral Biportal Endoscopic Approach for Symptomatic Adjacent Segment Disease: Case Report and Technical Note.Journal of orthopaedic case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical effect of unilateral biportal endoscopic-assisted transforaminal lumbar interbody fusion (UBE-TLIF) in the treatment of recurrent lumbar disc herniation (RLDH).
methodsThe clinical data of 44 patients with RLDH treated by UBE-TLIF in our hospital from August 2020 to December 2020 were analysed retrospectively. The study indicators included intraoperative blood loss, operation time, bed rest time, and hospital stay. The follow-up data included the visual analogue score (VAS) of low back pain, Japanese Orthopaedic Association score (JOA), Oswestry disability index (ODI) score, and the short form 36 health survey questionnaire (SF-36) score preoperatively and 1 week and 6 months postoperatively.
resultsThe average operation time was 179.15 ± 42.06 minutes, the average intraoperative blood loss was 132.67 ± 41.92 ml, the average bed rest time was 1.51 ± 0.42 days, and the average hospital stay was 4.82 ± 1.13 days. The VAS score of low back pain after the operation was lower than that before the operation (all P<0.0001). The ODI score, JOA score, and SF-36 scores at postoperative follow-up were significantly different from those before the operation (P<0.05). The satisfaction rate was 86.4% at 7 days after the operation and 95.4% at 6 months after the operation. The proportion of significant clinical efficacy was 18.2% (postoperative day 7) and 63.6% (postoperative month 6).
conclusionsUBE-TLIF has the advantages of a rapid recovery, less intraoperative blood loss, a short bed rest and hospital stay, and a good medium-term clinical effect. It is a safe, reliable minimally invasive technique for surgical treatment of RLDH.
Indexed as
Identifiers
35559367PMC9091115W4285743487What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.